NF-κB/IκB

CAY10512 is a potent NF-κB inhibitor that effectively suppresses the upregulation of NF-κB-sensitive proinflammatory microRNAs, including miRNA-9, miRNA-125b, miRNA-146a, and miRNA-155, in cerebrospinal fluid and extracellular environments. This compound significantly reduces the release of pro-inflammatory cytokines such as TNF-α, MCP-1, IL-8, and IL-6. CAY10512 is valuable for research applications focused on neuroinflammation, islet transplantation, and the regulation of microRNA.

SMU-L11-R is a selective TLR7 agonist that demonstrates an EC50 of 0.012 μM for human TLR7. This compound specifically activates TLR7, recruits MyD88, and initiates the MAPK/NF-κB signaling pathways, resulting in the secretion of pro-inflammatory cytokines such as TNF-α, IL-1β, and IL-6 in both mouse and human peripheral blood mononuclear cells. Additionally, SMU-L11-R promotes M1-like macrophage polarization and exhibits synergistic anti-tumor effects in combination with PD-L1 inhibitors through the upregulation of CD8+ T cells, making it a valuable tool for research in colorectal cancer.

Kaempferol 3-O-(2G-glucosylrutinoside)-7-O-glucoside is a potent anti-inflammatory agent that targets key signaling pathways, including NF-κB, MAPK, and Akt. This compound significantly reduces the production of inflammatory mediators such as nitric oxide (NO) and prostaglandin E2 (PGE2) in LPS-induced RAW 264.7 macrophages. Additionally, it suppresses the secretion of pro-inflammatory cytokines, including TNF-α, IL-1β, and IL-6, making it valuable for research into inflammation and related disorders.

Cudraflavone B is a prenylated flavonoid that functions as a dual inhibitor of COX-1 and COX-2, demonstrating significant anti-inflammatory and anti-tumor activity. This compound inhibits the translocation of nuclear factor κB (NF-κB) in macrophages, leading to decreased tumor necrosis factor α (TNFα) gene expression and secretion. Additionally, Cudraflavone B induces the mitochondrial apoptotic pathway while activating MAPK signaling pathways, including p38 and ERK, and upregulating SIRT1 expression. These mechanisms contribute to its efficacy in attenuating the growth of human oral squamous cell carcinoma cells, making it a valuable tool for cancer research.

rel-Cleroindicin F is an anti-inflammatory agent that targets the NF-κB signaling pathway. It effectively inhibits the production of nitric oxide (NO) and tumor necrosis factor-alpha (TNF-α) by downregulating NF-κB and its kinases in LPS-stimulated RAW 264.7 cells. This mechanism contributes to the suppression of inducible nitric oxide synthase expression, leading to decreased NO production. Rel-Cleroindicin F is valuable for research into inflammatory processes and potential therapeutic applications.

sEH-IN-21 is a potent inhibitor of soluble epoxide hydrolase (sEH), displaying IC50 values of 0.1 nM for both human and mouse sEH isoforms. This compound effectively inhibits NF-κB signaling pathways and demonstrates significant anti-inflammatory activity by reducing the release of pro-inflammatory cytokines IL-6 and TNF-α. Additionally, sEH-IN-21 helps maintain intestinal barrier integrity, making it a valuable tool for research on inflammatory bowel disease (IBD) and related inflammatory conditions.

CDN-3 is a cyclic dideoxy nucleotide derivative that functions as an antitumor agent. It stimulates the production of IFN-β and activates the IRF-3 and NF-κB signaling pathways, leading to the induction of type I interferons and pro-inflammatory cytokines such as IL-6 and TNF-α. CDN-3 effectively inhibits the proliferation of cancer cells, making it a valuable tool for investigating mechanisms of colon cancer progression and therapeutic strategies.

Panaxytriol is a potent NF-κB inhibitor that effectively reduces the nuclear translocation of NF-κB. This mechanism leads to decreased production of pro-inflammatory cytokines, including TNF-α, IL-1β, and IL-6, as well as nitric oxide in response to LPS stimulation. Additionally, Panaxytriol promotes the upregulation of CYP3A4 through activation of the nuclear receptors PXR and CAR. Its ability to improve motor dysfunction in mouse models of brain inflammation makes Panaxytriol valuable for research into neurodegenerative diseases, such as Alzheimer's disease.

Anti-inflammatory agent 41 is an effective inhibitor of lipopolysaccharide (LPS)-induced expression of pro-inflammatory cytokines IL-6 and TNF-α in J774A.1, THP-1, and LX-2 cells. This compound also inhibits the activation of the NF-κB signaling pathway. Its primary applications include investigating the mechanisms of inflammation and assessing potential therapeutic strategies in inflammation-related diseases.

Sabialimon P is a nitric oxide (NO) release inhibitor with an IC50 of 18.12 μM. This compound exhibits potent anti-inflammatory effects by significantly reducing the secretion of pro-inflammatory cytokines such as TNF-α, IL-6, and the enzyme iNOS in LPS-stimulated RAW264.7 macrophage cells. Additionally, Sabialimon P inhibits the expression of COX-2 and the NF-κB/p65 pathway, making it a valuable tool for research into inflammation-related pathways and potential therapeutic applications.

Anti-inflammatory agent 20 is a potent inhibitor of nitric oxide (NO) activity, demonstrating significant anti-inflammatory properties. This compound effectively suppresses lipopolysaccharide (LPS)-induced inflammation by inhibiting the activation of NF-κB and MAPK signaling pathways, leading to a reduction in pro-inflammatory cytokines such as IL-6, TNF-α, as well as the enzymes iNOS and COX-2. It serves as a valuable tool for research applications focused on inflammation and related signaling mechanisms.

Skimmianine is an orally active furoquiniline alkaloid present mainly in the Rutaceae family. Skimmianine has analgesic, antispastic, sedative, and anti-inflammatory properties. Skimmianine inhibits acetylcholinesterase (AChE) (IC50 = 8.6 μg/mL). Skimmianine exhibits cytotoxicity against a variety of cancer cell lines and genotoxicity. Skimmianine has antioxidant and anti-inflammatory effects on ischemia-reperfusion (IR) injury. Skimmianine exerts anti-inflammatory effects through activation of the phosphatidylinositol-3-kinase (PI3K)-protein kinase B (AKT) pathway. Skimmianine is neuroprotective by targeting the NF-κB activation pathway to prevent neuroinflammation. Skimmianine inhibits the release of histamine, intracellular Ca2+ signaling and protein kinase C signaling.

Kirenol is a diterpenoid compound, an orally active apoptosis inducer and signaling pathway regulator, with a Kd value of 5.47 μM against the target CK2. Kirenol promotes the cleavage of Bid into tBid, regulates the protein levels/phosphorylation of Bax, Bcl-2, p53 and p21, and induces caspase-independent apoptosis, S-phase cell cycle arrest, ROS accumulation and cytotoxicity in cancer cells. Kirenol activates the CK2/AKT and AMPK-mTOR-ULK1 pathways, inhibits the signaling of NF-κB, TGF-β/Smads and NLRP3 inflammasome, and regulates the GSK3β, BMP and Wnt/β-catenin pathways. Kirenol induces autophagy, mitophagy and osteoblast differentiation, promotes mitochondrial fusion, and exerts antioxidant, anti-inflammatory, antifibrotic, renoprotective, cardioprotective, neuroprotective and analgesic effects. Kirenol is applicable to research related to chronic myeloid leukemia, ischemic stroke, diabetic nephropathy, heart failure, acute lung injury and osteoporosis.

Isoginkgetin is a pre-mRNA splicing inhibitor that modulates splicing processes critical for gene expression. In addition to its primary function, Isoginkgetin inhibits the activities of the signaling proteins Akt and NF-κB, as well as matrix metalloproteinase-9 (MMP-9). This compound is known to inhibit the 20S proteasome, inducing apoptosis and activating autophagy, making it a valuable tool in cancer research and studies focused on cellular stress responses.

Oxaprozin is a potent, orally active cyclooxygenase (COX) inhibitor, demonstrating IC50 values of 2.2 μM for human platelet COX-1 and 36 μM for IL-1-stimulated human synovial cell COX-2. This compound exhibits significant anti-inflammatory activity and is known to inhibit the activation of NF-κB, promoting cell apoptosis. The inhibition of the Akt/IKK/NF-κB signaling pathway is a key mechanism underlying its anti-inflammatory properties, making Oxaprozin valuable for research in inflammation and related disorders.

Cryptanoside A is a potent Na+/K+-ATPase inhibitor derived from the stems of Cryptolepis dubia. This cardiac glycoside epoxide exhibits significant cytotoxic effects against various cancer cell lines. Additionally, Cryptanoside A enhances the expression of Akt and the p65 subunit of NF-κB, making it a valuable tool for studying cancer biology and the regulatory pathways involved in cell survival and proliferation.

Tianeptine-d12 is a deuterated analog of Tianeptine, functioning as a stable isotope for research applications. Tianeptine is classified as an atypical antidepressant, acting primarily as a moderate-intensity agonist of the μ-opioid receptor and showing lesser activity at the δ-opioid receptor. This compound modulates glutamate signaling by enhancing AMPA receptor activity while antagonizing NMDA receptors, contributing to its neuroprotective effects under stress and inflammation. Additionally, Tianeptine exhibits anti-inflammatory and antioxidant properties and has been shown to inhibit MMP-9 through the suppression of the PI3K/Akt-mediated NF-κB pathway, making it relevant for studies in depression, anxiety, and neuroprotection.

Acenocoumarol-d5 is a deuterium-labeled analog of Acenocoumarol, functioning as a Vitamin K antagonist. This anticoagulant exhibits key biological activities by inhibiting the MAPK/ERK/JNK signaling pathways, reducing the nuclear translocation of NF-κB p65, and activating the Akt/GSK3β signaling pathway. Acenocoumarol-d5 also induces apoptosis in A549 cells and effectively arrests the cell cycle at the S phase, making it useful for various research applications in cancer and cardiovascular studies.

7,4'-Dimethoxy-3-hydroxyflavone is a selective antagonist of Protease-Activated Receptor 4 (PAR4). It exhibits potent inhibition of PAR4-mediated human platelet aggregation with an IC50 value of 1.4 μM, effectively disrupting various PAR4 signaling pathways, including NF-κB, Ca2+/protein kinase C, Akt, ERK, and p38. This compound demonstrates potential therapeutic benefits in reducing vascular PAR4 expression and alleviating endothelial dysfunction and oxidative stress in diabetic models. Additionally, 7,4'-Dimethoxy-3-hydroxyflavone has been shown to prevent thrombosis in mice without prolonging bleeding time, suggesting its usefulness in cardiovascular research.

5,4'-Dihydroxy-6,8-dimethoxy-7-O-rhamnosyl flavone is a potent Akt inhibitor derived from Indigofera ovata. This compound effectively disrupts the PI3K/AKT and NF-κB signaling pathways, leading to the inhibition of cancer cell invasion and migration. Its biological activity supports research applications in cancer therapeutics and molecular signaling studies.

SPA0355 is a thiourea derivative that specifically targets RANKL-mediated signaling pathways to inhibit osteoclast formation in primary bone marrow-derived macrophages. This compound exhibits antioxidant and anti-inflammatory properties, while also suppressing the activation of MAPKs, Akt, and NF-κB pathways. Importantly, SPA0355 promotes osteoblast differentiation, enhances alkaline phosphatase activity, and stimulates mineral nodule formation. Due to its ability to protect against bone loss in ovariectomized mice, SPA0355 is valuable for investigating mechanisms and therapies related to postmenopausal osteoporosis.

Ipatasertib tosylate is a potent and selective ATP-competitive inhibitor of pan-Akt, exhibiting IC50 values of 5, 18, and 8 nM for Akt1, Akt2, and Akt3, respectively. By inhibiting Akt, Ipatasertib tosylate activates FoxO3a and NF-κB, resulting in p53-independent activation of PUMA and subsequent apoptosis in cancer cells. This compound demonstrates significant anti-tumor activity in xenograft mouse models, making it a valuable tool for cancer research and therapeutic development.

TAT-N15 is a selective inhibitor of the p55PIK protein, demonstrating significant anti-inflammatory activity and neuroprotective properties. This compound effectively suppresses the activation of key signaling pathways, including IL-6, IL-8, Akt, and NF-κB, while downregulating the expression of phosphorylated STAT3 and NF-κB. TAT-N15 is utilized in research exploring various conditions such as acute conjunctivitis, allergic rhinitis, chronic obstructive pulmonary disease (COPD), and stroke, making it a valuable tool for understanding and developing therapeutic strategies for these diseases.

Antcin K is a selective inhibitor targeting multiple signaling pathways, including PI3K/Akt, NF-κB, MEK1/2-ERK, p38, and AP-1. It upregulates IL-10 expression, effectively inhibiting pro-inflammatory factor production, reducing monocyte adhesion, and minimizing tissue damage, while promoting myogenesis. Antcin K exhibits robust anti-inflammatory and tissue protective properties, making it valuable for research applications related to inflammation-associated diseases such as periodontitis, rheumatoid arthritis, and skeletal muscle injury.

Calebin A is a potent inhibitor of the PI3K/Akt/mTOR pathway, as well as MAPK and NF-κB signaling pathways. It exhibits significant anti-tumor activity through epigenetic regulation and can suppress apoptosis while inhibiting autophagy. Additionally, Calebin A modulates adipogenesis, enhances thermogenic processes, and supports gut microbiota. This compound is suitable for research in various domains, including osteoarthritis, Alzheimer's disease, type 2 diabetes, malignant peripheral nerve sheath tumors, and colorectal cancer.

A2073 is a flavagline derivative that acts as a potent anti-erythroleukemia agent, primarily targeting the inhibition of cell proliferation in erythroleukemia cells. This compound induces cell cycle arrest and suppresses critical signaling pathways, including MAPK, NF-κB, and PI3K. A2073 engages in stable interactions with key cell cycle proteins such as CDK1, CCNA2, and PRIM1, demonstrating significant anti-proliferative efficacy against tumor cells while maintaining a favorable toxicity profile in zebrafish xenograft tumor models. This reagent is suitable for research applications focused on acute erythroleukemia.

Oxaprozin potassium is a potent cyclooxygenase (COX) inhibitor, demonstrating IC50 values of 2.2 μM for human platelet COX-1 and 36 μM for IL-1-stimulated human synovial cell COX-2. It not only exhibits anti-inflammatory activity but also inhibits the activation of NF-κB, inducing cell apoptosis. The inhibition of the Akt/IKK/NF-κB pathway is a key mechanism contributing to its anti-inflammatory effects, making it a valuable tool for research in inflammation and related cellular processes.

Acenocoumarol-d4 is a deuterated form of Acenocoumarol, functioning primarily as a stable isotope. As an anticoagulant, it operates through Vitamin K antagonism, effectively inhibiting the MAPK/ERK/JNK signaling pathways. This compound has been shown to reduce the nuclear translocation of NF-κB p65 and activate the Akt/GSK3β signaling pathways. Furthermore, Acenocoumarol-d4 induces apoptosis in A549 cells and specifically arrests the cell cycle at the S phase, making it valuable for research in cancer biology and pharmacology.

MJ33 is a competitive inhibitor of phospholipase A₂ (PLA₂), specifically effective in inhibiting acidic PLA₂ activity. By blocking the PLA₂ activity of Prdx6, MJ33 significantly reduces reactive oxygen species (ROS) production, thereby alleviating lung oxidative damage associated with ischemia-reperfusion injury. Additionally, MJ33 suppresses the invasive, migratory, and adhesive characteristics of prostate cancer cells through the downregulation of key signaling pathways, including MAPK, AKT, NF-κB, and AP-1. This reagent is ideal for research focused on ROS-related diseases and prostate cancer dynamics.

Pam2CSK4 is a TLR2 agonist that activates immune signaling pathways, leading to the expression of inducible nitric oxide synthase (iNOS) and nitric oxide (NO) in macrophage cell lines through TBK1 and MyD88. This compound stimulates the NF-κB and Bruton's tyrosine kinase pathways in platelets, enhancing interactions between platelets and endothelial cells. Pam2CSK4 promotes the expansion of myeloid-derived suppressor cells (MDSCs) and can suppress anti-tumor immune responses in the tumor microenvironment. Its applications span various diseases, including thromboinflammatory conditions, sepsis, atherosclerosis, and certain cancers, making it a valuable tool in immunological and therapeutic research.

Eudebeiolide B is an osteoclastogenesis inhibitor derived from Salvia plebeia R. Br. It functions by modulating RANKL-induced signaling pathways, including NF-κB, c-Fos, and calcium signaling. This compound is valuable for research into osteoclast-related diseases, providing insight into potential therapeutic strategies for bone resorption disorders.

Licoricidin (LCD) is a potent apoptosis inducer derived from Glycyrrhiza uralensis Fisch, demonstrating significant anti-cancer properties. It effectively inhibits SW480 colorectal cancer cells with an IC50 of 7.2 μM by promoting cell cycle arrest, apoptosis, and autophagy, making it a promising candidate for chemoprevention and chemotherapy. Additionally, Licoricidin suppresses lung metastasis through the inhibition of tumor angiogenesis and lymphangiogenesis, while improving the tumor microenvironment. In osteosarcoma models, Licoricidin enhances the cytotoxic effects of gemcitabine by inactivating the Akt and NF-κB signaling pathways. Furthermore, Licoricidin alleviates UVA-induced photoaging by scavenging reactive oxygen species and inhibiting MMP-1 activity, indicating its potential in topical anti-aging formulations.

Withangulatin A is a selective inhibitor of cyclooxygenase-2 (COX-2), demonstrating significant potential in the modulation of inflammatory and tumorigenic processes. This compound also interferes with the MAPK, NF-κB, and Akt/mTOR/p70S6K signaling pathways, thereby exhibiting notable antitumor and anti-inflammatory activities. Additionally, Withangulatin A has been shown to possess trypanocidal effects, making it useful for research in cancer, inflammation, and parasitic diseases.

Lupenone is a lupine-type triterpenoid that operates primarily through the PI3K/Akt/mTOR and NF-κB signaling pathways. It exhibits significant biological activities, including anti-inflammatory, antiviral, antidiabetic, and anticancer properties. This compound is valuable in research related to inflammation, viral infections, diabetes, and cancer therapeutics.

Niloticin is a tetracyclic triterpenoid that serves as an osteoclastogenesis inhibitor. It exhibits significant anti-viral, antioxidative, and mosquitocidal properties. By obstructing the RANKL-RANK interaction, Niloticin effectively suppresses the activation of key signaling pathways, including AKT, MAPK, and NF-κB, which are crucial in osteoclast differentiation and function. This compound is valuable for research focused on bone metabolism and related disorders.

Ethyl linoleate, an unsaturated fatty acid derivative, acts as an anti-inflammatory agent by inhibiting the Akt/GSK3β/β-catenin signaling pathway and blocking NF-κB activation. Additionally, it induces heme oxygenase-1 and inhibits tyrosinase, contributing to its whitening and anti-inflammatory properties. Ethyl linoleate promotes absorption of compounds and has notable implications for atherosclerosis research. Its applications extend to the study of various inflammatory diseases and cosmetic formulations.

3,4,5-Tricaffeoylquinic acid is an NF-κB inhibitor known for its ability to suppress tumor necrosis factor-α-induced inflammatory mediators in keratinocytes through the inhibition of Akt and NF-κB signaling pathways. This compound also induces cell cycle arrest at the G0/G1 phase, facilitates actin cytoskeleton organization, and promotes chromatin remodeling and neuronal differentiation in human neural stem cells. Additionally, 3,4,5-Tricaffeoylquinic acid is valuable for research into aging-associated diseases.

Syringaresinol is a lignan-type phytochemical that primarily targets anti-inflammatory pathways. It effectively inhibits the NF-κB and AKT signaling pathways in IL-1β-activated mouse chondrocytes, demonstrating significant anti-inflammatory activity. Additionally, Syringaresinol enhances the phosphorylation of AMPK and eNOS while increasing intracellular Ca2+ levels in HUVECs. Its ability to attenuate the progression of osteoarthritis in mouse models of DMM-induced osteoarthritis makes it a valuable reagent for research focused on OA.

Licochalcone E is a flavonoid compound that functions as a p38 MAPK inhibitor. It effectively inhibits the transcriptional activities of NF-κB and AP-1 by disrupting AKT and MAPK activation pathways. This compound is valuable for research focused on inflammation, cancer, and signal transduction pathways, offering insights into cellular mechanisms influenced by MAPK signaling.

7-Methoxy-1-tetralone is an effective antitumor agent that targets cancer cell proliferation and migration. This compound induces apoptosis in hepatocellular carcinoma (HCC) cells and reduces the protein levels of NF-κB, MMP2, MMP9, and phosphorylated AKT. In vivo studies demonstrate its antitumor efficacy in nude mice, with no observed adverse effects on body weight or organ indices.

Oxypeucedanin is a furanocoumarin derivative that acts as a potent blocker of the hKv1.5 current, with an IC50 of 76 nM. This compound demonstrates significant biological activities, including the induction of cell cycle arrest and apoptosis, as well as acting as a PI3K/AKT/NF-κB, MAPK, and ROS inhibitor. Its diverse applications include anticancer research, anti-inflammatory studies, antioxidant assays, and investigations into antiarrhythmic effects, making it a valuable reagent for various areas of biochemical research.

Fusaric acid is a potent dopamine β-hydroxylase inhibitor that reduces endogenous levels of norepinephrine and epinephrine in various tissues, including the brain, heart, spleen, and adrenal glands. By inducing oxidative stress and apoptosis, fusaric acid disrupts mitochondrial integrity and activates key apoptosis-related proteases such as Caspase-3/7, -8, and -9. Additionally, fusaric acid regulates pivotal apoptotic proteins, inhibits fibrosis-related signaling pathways including NF-κB and TGF-β1/SMADs, and mitigates collagen deposition. Its applications extend to myocardial fibrosis and cardiac hypertrophy research, as well as studies on esophageal and liver cancers.

Bavachalcone is a bacterial inhibitor known for its multifaceted biological activities. It induces apoptosis and enhances autophagy in HepG2 cancer cells, contributing to its anticancer potential. Additionally, Bavachalcone demonstrates anti-neuroinflammatory and antidepressant effects through modulation of the NF-κB pathway. It also inhibits osteoclast differentiation by interfering with ERK and Akt signaling pathways, as well as the expression of c-Fos and NFATc1, and shows a significant inhibitory effect on BACE-1 activity in vitro.

Isoscopoletin, also known as 6-Hydroxy-7-methoxycoumarin, primarily inhibits hepatitis B virus (HBV) replication. It demonstrates significant cytotoxic effects against human CCRF-CEM leukaemia cells and their multidrug-resistant subline, with IC50 values of 4.0 μM and 1.6 μM, respectively. Additionally, Isoscopoletin exhibits anti-inflammatory properties by modulating the MAPK/NF-κB/STAT/AKT signaling pathways, making it a valuable compound for research in virology and cancer biology.

Phellopterin is a furocoumarin compound recognized for its anticancer, anti-inflammatory, and anti-diabetic activities. It functions as a partial agonist of central benzodiazepine receptors and demonstrates significant anti-inflammatory properties by modulating key pathways such as SIRT1 and TLR4/NF-κB, which may aid in conditions like chronic inflammation and atopic dermatitis. Additionally, Phellopterin has been shown to inhibit ovarian cancer progression through the PU.1/CLEC5A/PI3K-AKT signaling loop and promotes adipocyte differentiation, contributing to its anti-diabetic effects. This compound is valuable for research in cancer, inflammation, diabetes management, and antiviral studies.

MR2938 is a potent acetylcholinesterase (AChE) inhibitor, exhibiting an IC50 of 5.04 μM. In addition to its enzymatic activity, MR2938 significantly reduces nitric oxide production, with an IC50 of 3.29 μM. This compound effectively mitigates neuroinflammation by inhibiting the MAPK/JNK and NF-κB signaling pathways. MR2938 is applicable for research focused on Alzheimer's disease and related neurodegenerative conditions.

Theophylline L-lysine is a soluble derivative of Theophylline that primarily acts as a phosphodiesterase (PDE) inhibitor. It effectively inhibits PDE3 activity, which leads to relaxation of airway smooth muscle and exhibits anti-inflammatory properties through the enhancement of IL-10 levels and the inhibition of NF-κB nuclear translocation. Additionally, Theophylline L-lysine induces apoptosis, making it a valuable compound for research applications in asthma and chronic obstructive pulmonary disease (COPD).

DOR Agonist 2 is a selective agonist of the Delta Opioid Receptor (DOR). It demonstrates the ability to inhibit TNF-α expression, prevent NF-κB translocation to the nucleus, and activate the G protein-mediated ERK1/2 signaling pathway. This compound is valuable in research focused on neurodegenerative diseases, facilitating studies on inflammation and neuroprotection mechanisms.

Candidusin A is a potent AMPK activator with a KD of 47.28 nM, isolated from the marine fungus Aspergillus candidus. This compound demonstrates significant cytotoxicity, inducing apoptosis in human prostate cancer cell lines such as 22Rv1, PC-3, and LNCaP. Additionally, Candidusin A reduces the expression of adipogenesis-related genes and fat deposition, while negatively regulating the NF-κB-TNFα inflammatory axis to mitigate inflammation. Its diverse biological activities make Candidusin A a valuable tool for research into non-alcoholic steatohepatitis (NASH) and liver injury.

SHP2-IN-45 is a highly selective allosteric inhibitor of SHP2 with potent oral bioavailability. This compound effectively downregulates the expression of pro-inflammatory cytokines, including IL-6, TNF-α, IL-1β, and iNOS, and inhibits the polarization of M1-type macrophages. Additionally, SHP2-IN-45 interferes with the NF-κB signaling pathway, making it a valuable tool for research in inflammation-related conditions such as sepsis and acute lung injury.